Form 4: Pacira BioSciences Director Mark Froimson Reports Acquisition of Equity and Options

Pacira BioSciences, Inc. Director Mark Froimson reported the acquisition of 6,163 restricted stock units and 11,279 stock options on June 11, 2025, as part of his compensation.

Summary

• Mark Froimson, a Director of Pacira BioSciences, Inc. (PCRX), reported new equity acquisitions.
• On June 11, 2025, Mr. Froimson acquired 6,163 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs are contingent rights to receive one share of common stock each and will vest on June 11, 2026, provided continuous service.
• Following this transaction, Mr. Froimson beneficially owns 20,636 shares of common stock.
• Additionally, Mr. Froimson acquired 11,279 stock options with an exercise price of $24.34.
• These stock options vest and become exercisable on June 11, 2026, contingent on continuous service, and expire on June 11, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The filing reports a routine, positive event of a director acquiring equity as compensation, aligning interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The acquisition of additional equity by a director aligns their interests with shareholders, potentially signaling confidence in the company's future.
• The acquisition of restricted stock units and stock options at no direct cost (for RSUs) or a set exercise price (for options) represents a form of compensation and incentive for continued service.
• The use of a Rule 10b5-1 plan indicates a pre-planned transaction, reducing concerns about opportunistic trading.

Risks

• The vesting of restricted stock units and exercisability of stock options are contingent on the reporting person remaining in continuous service with the issuer through the vesting date (June 11, 2026).

Future Outlook

The vesting of the acquired restricted stock units and the exercisability of the stock options are contingent on the director's continuous service with Pacira BioSciences, Inc. through June 11, 2026, indicating an expectation of continued tenure.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing is a routine disclosure of director compensation in the biotechnology/pharmaceutical industry. Such equity grants are common mechanisms to align executive and director interests with long-term shareholder value, particularly in companies like Pacira BioSciences, which rely on innovation and long-term strategic development.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a standard practice across the biotechnology and pharmaceutical sectors.
• While specific grant sizes vary based on company size, performance, and individual roles, the structure of performance-based vesting (continuous service) is typical for retaining key personnel and incentivizing long-term commitment.
• For example, similar equity compensation structures are observed at comparable biopharmaceutical companies like Amgen (AMGN) or Gilead Sciences (GILD) for their non-employee directors, though the specific values would differ based on market capitalization and compensation policies.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director generally aligns their interests with shareholders, potentially signaling confidence in the company's future.

Next Steps

• Continued service of Mark Froimson with Pacira BioSciences, Inc. through June 11, 2026, for the vesting of RSUs and exercisability of options.
• Potential exercise of stock options by Mark Froimson between June 11, 2026, and June 11, 2035.

Key Dates

Keywords

Pacira BioSciences, PCRX, Form 4, SEC filing, insider trading, director compensation, restricted stock units, stock options, equity acquisition, Mark Froimson, Rule 10b5-1